Resumo

MORA-BAUTISTA, Victor Manuel et al. 17-hydroxyprogesterone levels in blood from the heels of healthy full-term newborns. CES Med. [online]. 2017, vol.31, n.2, pp.127-135. ISSN 0120-8705.  https://doi.org/10.21615/cesmedicina.31.2.1.

Background and aim: Congenital adrenal hyperplasia is caused by enzymatic abnormalities in the synthesis of adrenal steroids. A pilot study was carried out to measure the values of 17- hydroxyprogesterone (17-OHP) in a sample of healthy full-term newborns; the present study aims to determine if birth weight or gender have differences on 17-OHP. Design: Transversal, descriptive, and prolective study. Methods: We included 81 healthy full-term newborns with normal prenatal controls born between July 18th, 2014, and August 1st, 2015. We took whole blood from heel pricks when the babies were three to five days old. Socioeconomic and clinical data were collected. Non-extracted 17-OHP ELISA was used. Its cut-off point was 20 ng/ml. If results were above cut-off point, babies were recalled for a new measure since transient high 17-hydroxyprogesterone levels are possible until babies are three months of age. Results: Gestational age varied between 37.0 to 41.5 weeks. Non-extracted 17-OHP levels ranged between 2.6 to 29.5 ng/mL (median: 11.5, IQR 7.2 to 15.1). 17-OHP levels variation per birth weight or gender were not found. Conclusions: Expected lesser variation in term newborns may explain these results. Quality issues should be solved before starting a screening program in our population because socioeconomic issues cause most problems in recalling positive screening babies.

Palavras-chave : 17-hydroxyprogesterone; Congenital adrenal hyperplasia; Screening; Newborn infant; Gestational age.

        · resumo em Espanhol     · texto em Inglês     · Inglês ( pdf )